Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma.

A reduction in tumor growth was observed early during the treatment and highly significant differences in tumor volume and luminiscence levels between control and EC-8042-treated tumors were observed as soon as 5-8 days after the beginning of the treatment (Figure 7A–7B ).

also in 132,142 other papers

Immunohistochemical analysis confirmed a decrease of C-MYC nuclear and cytosolic expression in EC-8042 treated tumors which did not reach statistical significance (Figure 8A & 8E ).

also in 111,027 other papers